Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

Fig. 1

a: FACS analysis of CEA cell surface expression for DLD-1 and MKN-45 cell lines and 8 PDOs. Gates were adjusted on the trough of CRC-03 and identical gates were used to quantify the percentage of CEAhi/lo cells in all lines. b: Summary of CEA hi/lo percentages and measured mean fluorescent intensities (MFIs) of the data in panel A. c: CEA protein expression heterogeneity identified in 6/11 CRC samples stained with the anti-CEA/CEACAM5 antibody HPA019758. Examples of CEA heterogeneity are highlighted by white (low CEA) and black (high CEA) arrows. Numbers indicate the Human Protein Atlas patient IDs. (images: courtesy of the Human Protein Atlas v18.proteinatlas.org; link: https://www.proteinatlas.org/ENSG00000105388-CEACAM5/pathology/tissue/colorectal+cancer)

Back to article page